Free AGACNP Practice Questions with Rationales: 12 Anticoagulant and Antiplatelet Items
By Roupen Odabashian, MD, FRCPC · Published · 10 min read
How we write and check articles: Editorial Policy.

Disclosure: Alma publishes this article and makes one of the study tools it discusses.
Short answer: below are 12 original AGACNP-style practice questions, all on one topic (anticoagulants and antiplatelet drugs) so that every answer can be keyed to a source we read. They are not a full question bank, and they are not ANCC questions. Each answer is taken from the FDA-approved label on DailyMed, opened on November 7, 2026, with the set ID and effective date in the Sources list.
This is exam study material for AGACNP students, not clinical guidance. The items test what a label says. They are not instructions for treating a patient, and they give no dosing instructions (item 7 only applies a ratio that the heparin label states). Labels are revised, so read the current one before you prescribe.
What does the AGACNP exam look like?
From the ANCC AGACNP certification page and test content outline[1][2]:
- 175 questions, of which 150 are scored and 25 are unscored pretest questions. The page allows 3.5 hours. The credential is valid for 5 years.
- The outline, effective March 17, 2025, splits the 150 scored questions into Core Competencies (36 questions, 24%), Clinical Practice (65, 43%) and Professional Role (49, 33%).
- Core Competencies includes advanced pathophysiology and advanced pharmacology. The outline also lists secondary classifications "whenever applicable", among them the hematopoietic body system and cardiovascular drug agents[2].
ANCC's own sample questions are linked from its certification page[1]. Use them to see the real format. The items below practice the drug knowledge the outline's pharmacology and cardiovascular and hematopoietic classifications point to.
The 12 questions
1. A patient taking warfarin has acute major bleeding and needs urgent reversal of the anticoagulant effect. Which product is indicated for urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist therapy in adults with acute major bleeding? A. Idarucizumab B. Protamine sulfate C. Prothrombin complex concentrate (human) D. Activated charcoal
2. A patient on dabigatran has life-threatening bleeding. Which agent is indicated when reversal of dabigatran's anticoagulant effect is needed in this situation? A. Vitamin K1 B. Idarucizumab C. Protamine sulfate D. Prothrombin complex concentrate
3. A patient's oral anticoagulant is being stopped for a reason other than pathological bleeding or completion of a course of therapy. What do the boxed warnings for apixaban, rivaroxaban and dabigatran say about that situation? A. Stopping has no effect on thrombotic risk B. Premature discontinuation increases the risk of thrombotic events, so consider coverage with another anticoagulant C. Stopping always requires vitamin K D. Stopping only matters with a mechanical valve
4. A patient receiving enoxaparin is about to have neuraxial anesthesia. Which of the following does the boxed warning list as increasing the risk of epidural or spinal hematoma? A. Concomitant NSAID use B. Normal renal function C. Age under 30 D. Taking the drug with food
5. A patient has been on heparin for six days. The platelet count is now 82,000 per mm3. Which action does the heparin label describe if the platelet count falls below 100,000 per mm3? A. Continue heparin and recheck in a month B. Promptly discontinue heparin, evaluate for HIT and HITT, and if necessary give an alternative anticoagulant C. Switch to the same drug at a lower dose D. Give protamine and continue heparin
6. Which statement about protamine sulfate and enoxaparin matches the Lovenox label? A. Protamine completely neutralizes anti-factor Xa activity B. Protamine has no effect on enoxaparin C. Protamine can largely neutralize enoxaparin, but anti-factor Xa activity is never completely neutralized (maximum about 60%) D. Vitamin K is the neutralizing agent
7. Using only the heparin label's statement that each mg of protamine sulfate neutralizes approximately 100 USP heparin units, and ignoring the label's note that less is needed as time passes, about how many mg of protamine would neutralize 5,000 USP units of heparin just given? A. 5 mg B. 25 mg C. 50 mg D. 500 mg
8. A patient who is a CYP2C19 poor metabolizer is considered for clopidogrel. What does the clopidogrel boxed warning say? A. The effect is increased B. Clopidogrel forms less active metabolite and has a diminished effect; consider another P2Y12 inhibitor C. It must be given with warfarin D. No testing exists for CYP2C19
9. Which history does the prasugrel label list as a contraindication? A. Prior transient ischemic attack or stroke B. Prior appendectomy C. Seasonal allergies D. Mild anemia of chronic disease
10. A patient on ticagrelor develops bleeding. According to the ticagrelor boxed warning, what should be done "if possible"? A. Stop ticagrelor at once in every case B. Manage the bleeding without discontinuing ticagrelor, because stopping increases the risk of subsequent cardiovascular events C. Double the dose D. Add prasugrel
11. Which statement matches the dabigatran label about mechanical prosthetic heart valves? A. Dabigatran is preferred over warfarin B. Dabigatran is contraindicated in patients with mechanical prosthetic valves C. Only the bioprosthetic valve is a problem D. Dabigatran is indicated for valve thrombosis
12. A patient develops skin necrosis within a few days of starting warfarin. What does the warfarin label say? A. Necrosis is expected and needs no change B. Discontinue warfarin if necrosis occurs, and consider alternative drugs if continued anticoagulation is necessary C. Double the dose D. Add vitamin K1 and continue
Answers and rationales
- C. The Kcentra label indicates it for urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist therapy in adults with acute major bleeding or the need for urgent surgery. Its boxed warning covers arterial and venous thromboembolic complications[3]. The warfarin label also describes vitamin K1, and says PCC, fresh frozen plasma or activated factor VII may be considered if reversal is urgent[4]. Idarucizumab is for dabigatran[5], and protamine is for heparin[6].
- B. Praxbind (idarucizumab) is indicated in patients treated with Pradaxa when reversal is needed for emergency surgery or urgent procedures and in life-threatening or uncontrolled bleeding[5].
- B. Each of the three labels says premature discontinuation of any oral anticoagulant increases the risk of thrombotic events and to consider coverage with another anticoagulant if it is stopped for a reason other than pathological bleeding or completion of a course[7][8][9].
- A. The enoxaparin boxed warning lists concomitant NSAIDs, platelet inhibitors and other anticoagulants, among other factors (indwelling epidural catheters, a history of traumatic or repeated punctures, a history of spinal deformity or surgery)[10].
- B. The heparin label says that if the platelet count falls below 100,000 per mm3, or recurrent thrombosis develops, promptly discontinue heparin, evaluate for HIT and HITT, and administer an alternative anticoagulant if necessary. It also says thrombocytopenia can occur 2 to 20 days after the start of heparin[6].
- C. The Lovenox label says injected enoxaparin may be largely neutralized by protamine but anti-factor Xa activity is never completely neutralized (maximum about 60%)[10].
- C. 5,000 units divided by 100 units per mg is 50 mg (recomputed with python). The label notes that the amount required decreases over time as heparin is metabolized[6]. This item tests the label's ratio, not a dosing instruction.
- B. The boxed warning says clopidogrel forms less active metabolite and has a reduced effect in CYP2C19 poor metabolizers, that tests are available to identify them, and to consider another platelet P2Y12 inhibitor[11].
- A. The prasugrel label contraindicates use in patients with a history of prior TIA or stroke (and in active pathological bleeding)[12].
- B. The ticagrelor boxed warning says: "If possible, manage bleeding without discontinuing BRILINTA. Stopping BRILINTA increases the risk of subsequent cardiovascular events"[13].
- B. The Pradaxa label says use is contraindicated in all patients with mechanical prosthetic valves, based on the RE-ALIGN trial, in which dabigatran had more thromboembolic events and more major bleeding than warfarin[9].
- B. The warfarin label says tissue necrosis usually appears within a few days of starting, to discontinue therapy if it occurs, and to consider alternative drugs if continued anticoagulation is necessary[4].
How do you use a set like this well?
- Read the stem for the verb. These items test one recall point each. The real exam tests application, so after each answer, change one fact in the stem and ask what would change.
- Keep a miss log. Write the label sentence that decided the answer, not only the letter.
- Space your reviews. In a randomized trial of 537 urology residents (Kerfoot and colleagues, 2007), residents who received questions spaced over 27 weeks scored significantly higher on later online tests than residents who received the same material in one bolus; the authors note the learning gains did not generalize to higher scores on the in-service examination[14].
How can you study this with Alma?
Alma's flashcards use the FSRS scheduler. You can make a card from each answer line above, and when a card gets "Again" twice in seven days, the flashcards sidebar offers "Quiz me on my misses", which turns those misses into practice questions. Alma's own quiz questions are five-option clinical vignettes made from your Learning Hub sources and books, so paste or upload your own review notes there; they do not come from Notebook notes. See Alma flashcards, the study schedule and the NP hub.
Frequently asked questions
Are these real ANCC questions? No. They are original items written for this page. ANCC links its own sample questions from the certification page[1].
How many questions are on the AGACNP exam? 175 questions, of which 150 are scored and 25 are unscored pretest questions, in 3.5 hours[1][2].
Why are all the questions about anticoagulants and antiplatelets? So that every answer could be keyed to a label we read. A broader set would need more sources opened and checked.
Where can I find the current label for a drug? On DailyMed, using the set ID in the Sources list. Always check the current version.
Sources
Opened on November 7, 2026. Labels are revised, so check the current version.
- ANCC Adult-Gerontology Acute Care Nurse Practitioner certification page: https://www.nursingworld.org/our-certifications/adult-gerontology-acute-care-nurse-practitioner/
- ANCC AGACNP-BC Test Content Outline, effective March 17, 2025: https://www.nursingworld.org/globalassets/certification/certification-specialty-pages/resources/test-content-outlines/agacnp-tco_09152026-for-webposting.pdf
- Kcentra (prothrombin complex concentrate, human), set ID eee1afb8-324c-42e4-8bf0-f0c9da5e6d42, effective May 16, 2023: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=eee1afb8-324c-42e4-8bf0-f0c9da5e6d42
- Jantoven (warfarin sodium) tablets, Upsher-Smith Laboratories, set ID 19a69a72-ac5d-45d5-a94d-a5aaecbe4730, effective October 28, 2026: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=19a69a72-ac5d-45d5-a94d-a5aaecbe4730
- Praxbind (idarucizumab) injection, Boehringer Ingelheim Pharmaceuticals, set ID c7400f8a-dcf4-a6df-6d07-983081b1bf34, effective January 23, 2024: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c7400f8a-dcf4-a6df-6d07-983081b1bf34
- Heparin sodium injection, Hospira, Inc., set ID c8c4edd2-ee9e-4558-6b8c-b83adc242a0a, effective August 25, 2026: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c8c4edd2-ee9e-4558-6b8c-b83adc242a0a
- Eliquis (apixaban) tablets, E.R. Squibb and Sons, set ID e9481622-7cc6-418a-acb6-c5450daae9b0, effective April 17, 2025: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e9481622-7cc6-418a-acb6-c5450daae9b0
- Xarelto (rivaroxaban) tablets, Janssen Pharmaceuticals, Inc., set ID 10db92f9-2300-4a80-836b-673e1ae91610, effective September 10, 2026: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=10db92f9-2300-4a80-836b-673e1ae91610
- Pradaxa (dabigatran etexilate) capsules, Boehringer Ingelheim Pharmaceuticals, set ID ba74e3cd-b06f-4145-b284-5fd6b84ff3c9, effective June 25, 2025: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9
- Lovenox (enoxaparin sodium) injection, Sanofi-Aventis U.S. LLC, set ID 5017a927-2a24-4f27-89f9-27c805bf7d59, effective May 28, 2026: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5017a927-2a24-4f27-89f9-27c805bf7d59
- Plavix (clopidogrel) tablets, Sanofi-Aventis U.S. LLC, set ID de8b0b67-eb25-4684-83b5-7ad785314227, effective May 30, 2025: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=de8b0b67-eb25-4684-83b5-7ad785314227
- Effient (prasugrel) tablets, Cosette Pharmaceuticals, set ID 69ea2d58-5353-4222-b61f-cab976fa7e5e, effective September 7, 2022: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=69ea2d58-5353-4222-b61f-cab976fa7e5e
- Brilinta (ticagrelor) tablets, AstraZeneca Pharmaceuticals LP, set ID f7b3f443-e83d-4bf2-0e96-023448fed9a8, effective May 7, 2026: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f7b3f443-e83d-4bf2-0e96-023448fed9a8
- Kerfoot BP, Baker HE, Koch MO, Connelly D, Joseph DB, Ritchey ML. Randomized, controlled trial of spaced education to urology residents in the United States and Canada. J Urol. 2007;177(4):1481-1487. PMID 17382760. DOI: https://doi.org/10.1016/j.juro.2006.11.074